29-May-2024 | Facts and Factors
Facts and Factors Market Research has published a new report titled “Biologics Outsourcing Market Size, Share, Growth Analysis Report By Product (Vaccines, Recombinant Protein, Antibody, Others), By Source (Microbial, Human, Others), By Applications (Stem Cell Research, Vaccine Development, Oncology, Blood Related Products Development, Tissue Related Products Testing, Cellular & Gene Therapy), By End User (Biotechnology Industries, Pharmaceutical Industries, Contract Development & Manufacturing Organization (CDMO)), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2024 – 2032”. According to the report, the global Biologics Outsourcing market is predicted to be valued at approximately USD 18.42 billion in 2023 and is expected to reach a value of around USD 56.35 billion by 2032, at a CAGR of around 13.2% between 2024 and 2032.
Biologics are medicines that are derived from natural sources. They are the drugs that vary from chemically synthesized ones including aspirin and antacids. Precisely, the products are extracted from antibodies, microorganisms, and cells. Biologics are outsourced as it can effectively treat rheumatoid arthritis, kidney failure, high cholesterol levels, Crohn's disorder, and asthma.
Browse the full “Biologics Outsourcing Market Size, Share, Growth Analysis Report By Product (Vaccines, Recombinant Protein, Antibody, Others), By Source (Microbial, Human, Others), By Applications (Stem Cell Research, Vaccine Development, Oncology, Blood Related Products Development, Tissue Related Products Testing, Cellular & Gene Therapy), By End User (Biotechnology Industries, Pharmaceutical Industries, Contract Development & Manufacturing Organization (CDMO)), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2024 – 2032” Report at https://www.fnfresearch.com/biologics-outsourcing-market
Rise in research activities pertaining to biologics will steer the market trends
A prominent increase in the research & development activities related to biologics is projected to spur the expansion of the biologics outsourcing industry during the forecast timeline. Apart from this, strong supply chain activities by the manufacturer are likely to attract the firms to offshore the biologics and this is likely to drive the business growth over the forecast timeline.
Furthermore, cost & time-saving benefits provided by biologics outsourcing activities will further propel the market expansion over the period from 2024 to 2032. Moreover, the biotech & pharma firms can save huge capital expenditure through biologics outsourcing and increase the invention and commercialization of the biologics over the forecast period, thereby prompting the market growth over the forecast timespan. Nevertheless, the high technical need for manufacturing biologics will impede business expansion.
Antibody to dominate the product segment over the forecast period
The segmental growth during the forecast timeline is owing to large-scale research activities carried out across the antibody engineering domain that will aid the monoclonal antibody-based product to remain a key biopharmaceuticals class over the coming years. Apart from this, the massive application of the antibodies for treating a large number of chronic ailments like asthma will further steer the segmental surge over the forecast timeline.
Recent Developments:
- October 2022: SAB Biotherapeutics, a company specializing in developing antibody-based therapies, announced a collaboration with Emergent, a Contract Development and Manufacturing Organization (CDMO). This partnership leverages Emergent's expertise to produce SAB's unique polyclonal antibody products.
- September 2022: Abzena Ltd., a leader in biopharmaceutical contract research services, announced an upgrade to its R&D facilities in the UK. This investment focuses on implementing Berkley Lights' Beacon system, a cutting-edge technology that accelerates antibody discovery by isolating individual B cells from targeted immune responses.
Vaccine & therapeutics development segment to record the highest CAGR during 2024-2032
The vaccine & therapeutics development segment is set to register the highest growth rate of more than 13.20% during the forecast timespan. The growth of the segment during the timeline from 2024 to 2032 is credited to the rise in the growing concerns related to the prevention of chronic ailments in people.
North America to account for the major revenue share of the overall market over the forecast timeframe
The regional market growth during the forecast timeline is attributed to the huge rate of biologic outsourcing and technological breakthroughs witnessed in the pharma and biotech business. Moreover, favorable government laws supporting the research pertaining to biologics along with the rapid transformation as well as paradigm shift witnessed in the field of biotechnology will prompt the regional market growth over the forecast period.
Report Scope
Report Attribute |
Details |
Market Size in 2023 |
USD 18.42 Billion |
Projected Market Size in 2032 |
USD 56.35 Billion |
CAGR Growth Rate |
13.2% CAGR |
Base Year |
2023 |
Forecast Years |
2024-2032 |
Key Market Players |
Abbvie Inc., Abzena Ltd., Avid Bioservices Inc., Bionova Scientific Inc., Boehringer Ingelheim International GmbH., Catalent Inc., Curia Global Inc., EirGenix Inc., Emergent, Eurofins Scientific, Fujifilm Diosynth Biotechnologies, Genentech Inc., Genscript Biotech Corporation, GL Biochem Corporation, JSR Corporation, KBI Biopharma, Lonza Group AG, Merck KGaA, Rentschler Biopharma SE, STC Biologics., Thermo Fisher Scientific Inc., Wuxi Biologics, and Others. |
Key Segment |
By Product, By Source, By Applications, By End User, and By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Some of the key participants in the business include Abbvie Inc., Abzena Ltd., Avid Bioservices, Inc., Bionova Scientific, Inc., Boehringer Ingelheim International GmbH., Catalent Inc., Curia Global, Inc., EirGenix, Inc., Emergent, Eurofins Scientific, Fujifilm Diosynth Biotechnologies, Genentech, Inc., Genscript Biotech Corporation, GL Biochem Corporation, JSR Corporation, KBI Biopharma, Lonza Group AG, Merck KGaA, Rentschler Biopharma SE, STC Biologics., Thermo Fisher Scientific Inc., Wuxi Biologics, and others.
This report segments the Biologics Outsourcing market as follows:
By Product
- Vaccines
- Recombinant Protein
- Antibody
- Monoclonal Antibody
- Bi-specific Antibody
- Antibody Drug Conjugates
- Others
By Source
By Applications
- Stem Cell Research
- Vaccine Development
- Oncology
- Blood Related Products Development
- Tissue Related Products Testing
- Cellular & Gene Therapy
By End User
- Biotechnology Industries
- Pharmaceutical Industries
- Contract Development & Manufacturing Organization (CDMO)
Biologics Outsourcing Market: By Regional Segment Analysis
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
